Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)
C-Bridge Capital Signs a Development & Commercialization Agreement with Samsung Bioepis for Biosimilars in China
Shots:
- The company initiates P-III clinical trial to evaluate the efficacy, safety, tolerability, PK, and immunogenicity of SB17 vs Stelara in a ratio (1:1) in patients with moderate to severe plaque psoriasis
- Additionally, patients either continue on Stelara or transition to SB17 @28wks. The IPs (SB17 or Stelara, q12w) will be administered @0, 4 and for up to 40wks. and the last assessment will be performed @52wks.
- The company continues to advance a broad pipeline of biosimilar candidates covering therapeutic areas, including immunology, oncology, ophthalmology, hematology, endocrinology, and gastroenterology
Click here to read full press release/ article | Ref: Samsung Bioepis | Image: PR Newswire